Mirum Pharmaceuticals Inc (MIRM) Stock Price, Quote & News

Company Profile

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercializat...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 667 4085

Website: www.mirumpharma.com

Address:

950 Tower Lane, Suite 1050, Foster City, United States

Night_Owl_Biotech Oct. 21 at 7:40 PM

$FOLD continues to trade at lower multiples of projected sales versus 3 peers with like dollar forecasts & gross margin profiles. FOLD is currently defending its patent rights against a generic pharma hoping to sell a biosimilar. We suspect this could be the reason why FOLD does not trade at like multiples versus its peers $MIRM $TARS $KNSA Again by peers we mean those commercial-stage bios with similar revenue projections & patent lives. This is not investment advice. $IBB

2 · Reply

Datum Oct. 21 at 3:32 PM

$MIRM is this drop related to anything?

3 · Reply

JarvisFlow Oct. 16 at 6:00 PM

Morgan Stanley has adjusted their stance on Mirum Pharmaceuticals ( $MIRM ), setting the rating to Overweight with a target price of 75 → 81.

0 · Reply

LMXPERTEN Oct. 15 at 7:14 PM

$MIRM we see a new basis? 75?

2 · Reply

LMXPERTEN Oct. 15 at 10:06 AM

$MIRM recruiting for Fragile X. https://clinicaltrials.gov/study/NCT07209462?term=Mirum&rank=7 Thats why we got that running in the 9th

0 · Reply

ZacksResearch Oct. 14 at 5:39 PM

$MIRM — Can Livmarli keep powering the growth story? Livmarli is still Mirum’s main revenue driver and is expected to have lifted the company’s top line in Q3 — the key question is how much momentum it still has left. Full earnings outlook here 👉 https://www.zacks.com/stock/news/2768439/will-livmarli-continue-to-drive-mirums-top-line-in-q3-earnings?cid=sm-stocktwits-2-2768439-teaser-16050&ADID=SYND_STOCKTWITS_TWEET_2_2768439_TEASER_16050

0 · Reply

ZacksResearch Oct. 14 at 4:39 PM

$MIRM up 74.6% YTD — is this biotech gem still a buy? 🚀 📈 Livmarli sales soared 79.1% in the first half of 2025, leading to a revised revenue guidance of $490-$510M after Q2 earnings call. 💊 Acquired Travere’s bile acid products, diversifying income streams. 🔍 Zacks Rank #2 (Buy) with narrower loss estimates — momentum continues! Discover more on MIRM’s growth potential 👉 https://www.zacks.com/stock/news/2768439/will-livmarli-continue-to-drive-mirums-top-line-in-q3-earnings?cid=sm-stocktwits-2-2768439-body-16029&ADID=SYND_STOCKTWITS_TWEET_2_2768439_BODY_16029

0 · Reply

xbibackto65s Oct. 10 at 4:31 PM

$MIRM added more

0 · Reply

LMXPERTEN Oct. 7 at 8:42 PM

$MIRM so strong. 72-73 stats. BO at 100+ 😎

1 · Reply

MomentumLurker Oct. 5 at 11:57 AM

$MIRM Healthcare technology growth. Testing resistance level. Volume expansion needed for continuation. Sector momentum.

0 · Reply

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 8, 2025, 11:13 AM EDT - 7 weeks ago

Mirum Pharmaceuticals, Inc. (MIRM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 8:00 AM EDT - 7 weeks ago

Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study

Aug 27, 2025, 4:02 PM EDT - 2 months ago

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 11, 2025, 9:48 AM EDT - 2 months ago

Mirum Pharmaceuticals: Q2 Results Continue To Show Positive Momentum

Aug 6, 2025, 9:09 PM EDT - 2 months ago

Mirum Pharmaceuticals, Inc. (MIRM) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:01 PM EDT - 2 months ago

Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 30, 2025, 4:01 PM EDT - 3 months ago

Mirum Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025

May 19, 2025, 8:30 AM EDT - 5 months ago

Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer

May 9, 2025, 8:30 AM EDT - 6 months ago

Volixibat Data from Mirum's VANTAGE PBC Study Showcased at EASL

May 7, 2025, 9:17 PM EDT - 6 months ago

Mirum Pharmaceuticals, Inc. (MIRM) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:01 PM EDT - 6 months ago

Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 4, 2025, 6:45 PM EDT - 6 months ago

Mirum Pharmaceuticals: A Respectable Liver, Rare Disease Franchise With Pipeline Opportunities

Apr 30, 2025, 8:30 AM EDT - 6 months ago

Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

Apr 28, 2025, 8:30 AM EDT - 6 months ago

Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses

Apr 14, 2025, 8:30 AM EDT - 7 months ago

Mirum's LIVMARLI Now FDA Approved in Tablet Formulation

Mar 27, 2025, 8:30 AM EDT - 7 months ago

LIVMARLI Now Approved in Japan for ALGS and PFIC

Mar 24, 2025, 5:17 PM EDT - 7 months ago

Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call

Feb 27, 2025, 7:10 AM EST - 8 months ago

Mirum Pharmaceuticals, Inc. (MIRM) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:01 PM EST - 8 months ago

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Feb 24, 2025, 8:30 AM EST - 8 months ago

Mirum's CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)

Feb 21, 2025, 12:01 PM EST - 8 months ago

US FDA approves Mirum Pharma's genetic disorder drug

Feb 19, 2025, 4:04 PM EST - 8 months ago

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025

Jan 13, 2025, 8:30 AM EST - 10 months ago

Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates

Jan 8, 2025, 11:05 AM EST - 10 months ago

Top 5 Commercial Biotech Buyout Candidates: Mirum Pharmaceuticals (No. 3)

Jan 6, 2025, 4:04 PM EST - 10 months ago

Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 25, 2024, 10:00 AM EST - 10 months ago

Mirum Pharma: Buy At Dips For Volixibat Potential

Nov 14, 2024, 8:00 AM EST - 1 year ago

Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD's The Liver Meeting

Nov 12, 2024, 1:51 PM EST - 1 year ago

Mirum Pharmaceuticals, Inc. (MIRM) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 8:00 AM EST - 1 year ago

Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 4, 2024, 4:30 PM EST - 1 year ago

Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Oct 31, 2024, 8:30 AM EDT - 1 year ago

Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis

Aug 9, 2024, 9:10 PM EDT - 1 year ago

Mirum Pharmaceuticals, Inc. (MIRM) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:01 PM EDT - 1 year ago

Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 31, 2024, 4:30 PM EDT - 1 year ago

Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024

Jul 25, 2024, 8:30 AM EDT - 1 year ago

Mirum's LIVMARLI Now Approved for PFIC in Patients 12 Months and Older

Jul 17, 2024, 3:48 AM EDT - 1 year ago

Bullish On Mirum Pharmaceuticals: Enhanced Portfolio With Strategic Acquisition

Jul 8, 2024, 8:30 AM EDT - 1 year ago

Mirum Pharmaceuticals' LIVMARLI Approved in the European Union for Patients with PFIC

Jun 28, 2024, 8:30 AM EDT - 1 year ago

Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX

Jun 27, 2024, 4:48 PM EDT - 1 year ago

3 Biotech Stocks For The Second Half Of 2024

ALT NTLA

Jun 17, 2024, 10:53 AM EDT - 1 year ago

Mirum Pharmaceuticals Highlights Encouraging Data For Rare Liver Disease Therapy From Two Mid-Stage Studies

Jun 17, 2024, 8:00 AM EDT - 1 year ago

Mirum's Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies

Jun 16, 2024, 5:00 PM EDT - 1 year ago

Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024

Jun 5, 2024, 4:05 PM EDT - 1 year ago

Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

May 31, 2024, 8:30 AM EDT - 1 year ago

Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older

May 29, 2024, 8:30 AM EDT - 1 year ago

Long-Term Data from Mirum's LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress

May 18, 2024, 7:00 AM EDT - 1 year ago

Mirum Pharmaceuticals' LIVMARLI Data Showcased at ESPGHAN Annual Meeting

May 11, 2024, 2:25 PM EDT - 1 year ago

Mirum Pharmaceuticals, Inc. (MIRM) Q1 2024 Earnings Call Transcript

May 8, 2024, 4:02 PM EDT - 1 year ago

Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Night_Owl_Biotech Oct. 21 at 7:40 PM

2 · Reply

Datum Oct. 21 at 3:32 PM

$MIRM is this drop related to anything?

3 · Reply

JarvisFlow Oct. 16 at 6:00 PM

Morgan Stanley has adjusted their stance on Mirum Pharmaceuticals ( $MIRM ), setting the rating to Overweight with a target price of 75 → 81.

0 · Reply

LMXPERTEN Oct. 15 at 7:14 PM

$MIRM we see a new basis? 75?

2 · Reply

LMXPERTEN Oct. 15 at 10:06 AM

$MIRM recruiting for Fragile X. https://clinicaltrials.gov/study/NCT07209462?term=Mirum&rank=7 Thats why we got that running in the 9th

0 · Reply

ZacksResearch Oct. 14 at 5:39 PM

0 · Reply

ZacksResearch Oct. 14 at 4:39 PM

0 · Reply

xbibackto65s Oct. 10 at 4:31 PM

$MIRM added more

0 · Reply

LMXPERTEN Oct. 7 at 8:42 PM

$MIRM so strong. 72-73 stats. BO at 100+ 😎

1 · Reply

MomentumLurker Oct. 5 at 11:57 AM

$MIRM Healthcare technology growth. Testing resistance level. Volume expansion needed for continuation. Sector momentum.

0 · Reply

xbibackto65s Sep. 26 at 3:21 PM

$MIRM adding

1 · Reply

IN0V8 Sep. 24 at 2:26 PM

$MIRM Buy TD Cowen initiates coverage with buy rating; PT $95

0 · Reply

notreload_ai Sep. 24 at 12:06 PM

TD Cowen started coverage of $MIRM with a Buy rating and a $95 price target. The company has three successful products for rare liver diseases and is developing volixibat (also known as SHP626) for pruritus.

1 · Reply

ZacksResearch Sep. 23 at 2:49 PM

$CRMD or $MIRM — Which biotech stock is the better bet? CorMedix’s DefenCath delivered $78.8M in 2025 H1 sales, propelling a full-year revenue guidance boost, while $MIRM’s Livmarli sales soared 79.1% YoY in H1 2025. Yet, CRMD’s Zacks Rank #1 (Strong Buy) and strategic Melinta acquisition give it a significant edge. Find out why CRMD is the stronger pick 👉 https://www.zacks.com/stock/news/2755750/crmd-vs-mirm-which-specialized-biotech-stock-is-the-better-pick?cid=sm-stocktwits-2-2755750-body-13685&ADID=SYND_STOCKTWITS_TWEET_2_2755750_BODY_13685

0 · Reply

ZacksResearch Sep. 23 at 1:49 PM

$CRMD vs. $MIRM — which biotech is the smarter play? Both are carving out niches with strong therapy launches, rising sales, and acquisitions fueling momentum. Full comparison here 👉 https://www.zacks.com/stock/news/2755750/crmd-vs-mirm-which-specialized-biotech-stock-is-the-better-pick?cid=sm-stocktwits-2-2755750-teaser-13677&ADID=SYND_STOCKTWITS_TWEET_2_2755750_TEASER_13677

0 · Reply

davirom Sep. 19 at 2:27 AM

$MIRM shall we go for a 92$ buyout? I am revising my selling price ⬆️ month after month 😅

1 · Reply

anachartanalyst Sep. 12 at 4:02 PM

$MIRM https://anachart.com/wp-content/uploads/ana_temp/1757692918_soc-img.jpg

0 · Reply

Engrdon Sep. 12 at 2:37 PM

$MIRM So JP Morgan bumped up the TP to $77.00. It seems like they are about 1/3 the way to home. 😁 MIRM’s got proven products that are growing fast, a pipeline that’s partially de-risked in areas where people really need it, and a company with a proven track record that could make billions of dollars, AND they must look great to big Pharma. I just wish I’d bought more…

1 · Reply

JarvisFlow Sep. 12 at 11:30 AM

JP Morgan updates rating for Mirum Pharmaceuticals ( $MIRM ) to Overweight, target set at 53 → 77.

0 · Reply

chrssyngrg978 Sep. 12 at 10:58 AM

$MIRM Mirum Pharmaceuticals price target raised by $24 at JPMorgan

1 · Reply

joaneegell Sep. 11 at 3:44 PM

$MIRM OK - after a couple months and a nice 30% climb I guess I'm out for a while. This looks like it's drifting back down a bit.

1 · Reply

LMXPERTEN Sep. 10 at 8:26 PM

$MIRM down on no volume

0 · Reply

Market Cap	3.52B
Revenue (ttm)	336.89M
Net Income (ttm)	-87.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-26.10%
Debt to Equity Ratio	0.00

Volume	399,800
Avg Vol	718,628
Day's Range	N/A - N/A
Shares Out	50.24M
Stochastic %K	46%
Beta	0.81
Analysts	Strong Sell
Price Target	$83.55